176 related articles for article (PubMed ID: 37273007)
1. Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study.
Shou L; Chen J; Shao T; Zhang Y; Zhao S; Chen S; Shu Q
Support Care Cancer; 2023 Jun; 31(7):375. PubMed ID: 37273007
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand-Foot Skin Reaction.
Shou L; Shao T; Zhao F; Chen S; Chen Q; Shu Q
Cancer Manag Res; 2021; 13():45-53. PubMed ID: 33442293
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
Li JR; Yang CR; Cheng CL; Ho HC; Chiu KY; Su CK; Chen WM; Wang SS; Chen CS; Yang CK; Ou YC
Support Care Cancer; 2013 Mar; 21(3):907-11. PubMed ID: 23262811
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.
Zhu Y; Zhang X; Lou X; Chen M; Luo P; He Q
Clin Exp Pharmacol Physiol; 2018 Jul; 45(7):659-667. PubMed ID: 29543385
[TBL] [Abstract][Full Text] [Related]
6. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
8. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
Anderson R; Jatoi A; Robert C; Wood LS; Keating KN; Lacouture ME
Oncologist; 2009 Mar; 14(3):291-302. PubMed ID: 19276294
[TBL] [Abstract][Full Text] [Related]
9. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial.
Nishizawa A; Shinozaki E; Wakatsuki T; Satoh T; Yamazaki N; Oyamada S; Ariyoshi K; Kihara K; Tsuboi M; Yamaguchi K
BMC Cancer; 2023 May; 23(1):401. PubMed ID: 37142953
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of the Shouzu Ning Decoction Treatment Versus Halometasone Plus Celecoxib Treatment in Patients With Grade 2 HFSR: A Randomized Clinical Trial.
Shou L; Shao T; Chen J; Zhang Y; Shu Q
Integr Cancer Ther; 2023; 22():15347354231168796. PubMed ID: 37082777
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
[TBL] [Abstract][Full Text] [Related]
14. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Belum VR; Wu S; Lacouture ME
Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
[TBL] [Abstract][Full Text] [Related]
15. Adherence to a topical moisturizing preparation for regorafenib-related hand-foot skin reaction.
Sato J; Ishikawa H; Hamauchi S; Yamawaki Y; Mori K; Kiyohara Y; Yoshikawa S; Yamazaki K; Yasui H; Shino M
J Oncol Pharm Pract; 2020 Mar; 26(2):361-367. PubMed ID: 31106665
[TBL] [Abstract][Full Text] [Related]
16. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
[TBL] [Abstract][Full Text] [Related]
17. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Lacouture ME; Reilly LM; Gerami P; Guitart J
Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
[TBL] [Abstract][Full Text] [Related]
18. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
Ochi M; Kamoshida T; Ohkawara A; Ohkawara H; Kakinoki N; Hirai S; Yanaka A
World J Gastroenterol; 2018 Jul; 24(28):3155-3162. PubMed ID: 30065561
[TBL] [Abstract][Full Text] [Related]
19. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Jatoi A; Ou FS; Ahn DH; Zemla TJ; Le-Rademacher JG; Boland P; Ciombor KK; Jacobs NL; Pasche B; Cleary JM; McCune JS; Pedersen KS; Barzi A; Chiorean EG; Heying EN; Lenz HJ; Sloan JA; Grothey A; Lacouture ME; Bekaii-Saab T
Oncologist; 2021 Jul; 26(7):610-618. PubMed ID: 33604969
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E
Shichiri H; Yamamoto K; Tokura M; Ishida T; Uda A; Bito T; Nishigori C; Nakagawa T; Hirano T; Yano I; Hirai M
Biochem Biophys Res Commun; 2017 Apr; 485(2):227-233. PubMed ID: 28237700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
